Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 18;21(2):228.
doi: 10.3390/molecules21020228.

Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus

Affiliations

Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus

Shwu-Chen Tsay et al. Molecules. .

Abstract

A series of new conjugated compounds with a -SCH₂- linkage were synthesized by chemical methods from imidazole and coumarin derivatives. The experimental results indicate that of the twenty newly synthesized imidazole-coumarin conjugates, three of them exhibited appealing EC50 values (5.1-8.4 μM) and selective indices >20 against hepatitis C virus. Their potency and selectivity were increased substantially by modification of their structure with two factors: imidazole nucleus with a hydrogen atom at the N(1) position and coumarin nucleus with a substituent, such as Cl, F, Br, Me, and OMe. These guidelines provide valuable information for further development of conjugated compounds as anti-viral agents.

Keywords: coumarin; hepatitis C virus; imidazole; nitrogen heterocycles; structure–activity relationships.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
General structure of targed imidazole–coumarin conjugates.
Scheme 1
Scheme 1
Synthesis of imidazole–coumarin conjugates.
Scheme 2
Scheme 2
Synthesis of (1-ribofuranosyl)imidazole–coumarin conjugates.
Scheme 3
Scheme 3
Synthesis of inosine– and guanosine-coumarin conjugates.
Figure 2
Figure 2
Structure of benzimidazole–coumarin conjugates.

Similar articles

Cited by

References

    1. Murphy D.G., Sablon E., Chamberland J., Fournier E., Dandavino R., Tremblay C.L. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J. Clin. Microbiol. 2015;53:967–972. doi: 10.1128/JCM.02831-14. - DOI - PMC - PubMed
    1. Oze T., Hiramatsu N., Mita E., Akuta N., Sakamoto N., Nagano H., Itoh Y., Kaneko S., Izumi N., Nomura H., et al. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol. Res. 2013;43:35–43. doi: 10.1111/j.1872-034X.2012.01056.x. - DOI - PubMed
    1. Kwong A.D., Kauffman R.S., Hurter P., Mueller P. Discovery and development of telaprevir: An NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 2011;29:993–1003. doi: 10.1038/nbt.2020. - DOI - PubMed
    1. Thibault P.A., Wilson J.A. Targeting miRNAs to treat hepatitis C virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol. Res. 2013;75:48–59. doi: 10.1016/j.phrs.2013.03.004. - DOI - PubMed
    1. Hulskotte E.G.J., Feng H.-P., Xuan F., Gupta S., van Zutven M.G.J.A., O’Mara E., Wagner J.A., Butterton J.R. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob. Agents Chemother. 2013;57:2582–2588. doi: 10.1128/AAC.02347-12. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources